Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Benchmark Maintains Speculative Buy on Biolase, Lowers Price Target to $0.4

Author: Benzinga Newsdesk | March 22, 2024 01:42pm

Benchmark analyst Bruce Jackson maintains Biolase (NASDAQ:BIOL) with a Speculative Buy and lowers the price target from $2.5 to $0.4.

Posted In: BIOL